TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

导出原文传递

翻译打印收藏纠错

作者： Nievergall, E. ^[1] ; Reynolds, J. ^[2] ; Kok, C. H. ^[3] ; Watkins, D. B. ^[4] ; Biondo, M. ^[5] ; Busfield, S. J. ^[6] ; Vairo, G. ; Fuller, K. ; Erber, W. N. ; Sadras, T. ; Grose, R. ; Yeung, D. T. ; Lopez, A. F. ; Hiwase, D. K. ; Hughes, T. P. ; White, D. L.

作者单位： Monash Univ, Alfred Ctr, Fac Med Nursing & Hlth Sci, Biostat Platform, Melbourne, Vic 3004 ^[1] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia ^[2] Univ Adelaide, Sch Med, Adelaide, SA, Australia ^[3] CSL Ltd, Parkville, Vic, Australia ^[4] SAHMRI, Canc Theme, North Terrace, Adelaide, SA 5000, Australia ^[5] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia ^[6]

发布时间 2017-04-06

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Leukemia

2016年30卷6期

1263-1272页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Leukemia

相似文献

Leukemia

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

TGF-alpha and IL-6 plasma levels selectively identify CML patients who fail to achieve an early molecular response or progress in the first year of therapy

Leukemia

相似文献

Leukemia

相关期刊

检索历史清除